Research
Hormonal
GLP-1 receptor agonists have demonstrated cardioprotection in patients with type 2 diabetes and heart failure.
Incorporating GLP-1RAs into treatment plans may improve cardiovascular outcomes in diabetic patients.
StrongSupportsmedium confidence
Metformin, sodium-glucose cotransporter 2 inhibitors (SGLT2i) and more recently, glucagon-like peptide-1 receptor agonists (GLP-1RAs), have demonstrated cardioprotection with their administration.
Why this rating
The claim is supported by clinical evidence of drug efficacy.
Source
Advances in incretin therapies for targeting cardiovascular disease in diabetes
Timothy D. Roberts et al. · Journal of Molecular and Cellular Cardiology · 2025
DOI 10.1016/j.yjmcc.2025.03.007
reviewCited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →